Shares of Bioverativ Inc (NASDAQ:BIVV) have received a consensus recommendation of “Hold” from the seventeen research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, nine have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $61.46.

A number of equities analysts recently weighed in on BIVV shares. Cowen and Company raised Bioverativ from a “market perform” rating to an “outperform” rating in a report on Monday, July 10th. Zacks Investment Research raised Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 price objective on the stock in a report on Tuesday, July 25th. Royal Bank Of Canada started coverage on Bioverativ in a report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price objective on the stock. Evercore ISI started coverage on Bioverativ in a report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price objective on the stock. Finally, Argus raised Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a report on Wednesday, September 20th.

COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/02/bioverativ-inc-bivv-receives-average-recommendation-of-hold-from-brokerages.html.

Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.25. The company had revenue of $291.60 million for the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. Bioverativ’s quarterly revenue was up 27.2% on a year-over-year basis.

In other news, Director Brian S. Posner purchased 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The shares were bought at an average cost of $59.19 per share, for a total transaction of $59,190.00. Following the completion of the transaction, the director now directly owns 6,693 shares of the company’s stock, valued at approximately $396,158.67. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Louis J. Paglia purchased 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were purchased at an average price of $59.70 per share, for a total transaction of $119,400.00. Following the completion of the transaction, the director now directly owns 5,056 shares of the company’s stock, valued at $301,843.20. The disclosure for this purchase can be found here.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BIVV. TCI Wealth Advisors Inc. bought a new stake in shares of Bioverativ during the third quarter valued at approximately $186,000. Canada Pension Plan Investment Board purchased a new position in Bioverativ during the third quarter valued at $194,000. Essex Investment Management Co. LLC purchased a new position in Bioverativ during the third quarter valued at $238,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in Bioverativ during the third quarter valued at $242,000. Finally, Traynor Capital Management Inc. purchased a new position in Bioverativ during the third quarter valued at $244,000. Institutional investors own 92.93% of the company’s stock.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Analyst Recommendations for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.